The genitourinary cancer program features expert discussions on new evidence and evolving approaches in prostate, renal, and bladder cancers. Below, meet the co-chair and review program highlights that explore how emerging data and diverse perspectives inform clinical decision-making in GU oncology.
More Information Coming Soon. 

Agenda Highlights

March 14, 4:25 PM
First-Line Strategies in Metastatic Renal Cancer: Doublet Immune Checkpoint Blockade vs Immune Checkpoint Blockade Plus VEGFR TKI
March 15, 2:10 PM
First-Line Strategies in Metastatic Renal Cancer: Doublet Immune Checkpoint Blockade vs Immune Checkpoint Blockade Plus VEGFR TKI
March 15, 4:25 PM
Treatment of Platinum-Sensitive and Resistant Recurrent Ovarian Cancer: Optimizing Outcomes with Currently Available Therapies – The Regulatory Standard Is the Treatment Standard vs Rethinking Recurrent Ovarian Cancer – ADCs, New Taxane Combinations, Bisp
Back to top